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OBJECTIVES: Cost of illness (COI) studies can identify and measure all the costs of
a particular disease, including the direct, indirect and intangible dimension. They
provide estimates about the economic impact of costly disease. Alzheimer disease
(AD) is a relevant example to review cost of illness studies because of its costliness.
The aim of this study was to review relevant published cost studies of AD to ana-
lyze the method used and to identify which dimension had to be improve from a
methodological perspective. METHODS: We described the key points of cost study
methodology. Cost studies on AD were systematically reviewed. The methodolog-
ical choices of the studies that estimating AD costs were analyzed using an ana-
lytical grid which contains the main methodological items of COI studies.
RESULTS: Seventeen articles were retained. Depending on studies, annual total
cost of AD per patient varies from $2,935 to $52,954.Disease definition was made
mainly with NINCDS-ADRDA criterion and with MMSE for severity stage. The so-
cietal perspective was the mainly used perspective and both direct costs and in-
formal costs were assessed in 14 studies. A Prospective record was realized in 13
studies with a bottom-up approach. Resource consumption was mainly estimate
with questionnaires. Valuation of unit costs was mostly made with national esti-
mates, reimbursement tariffs and gross wage of a close substitute. Most studies
present results clearly and consistently set out in relation to the methods adopted.
Nevertheless, methods, data sources, and estimated cost categories in each study
varied widely. The review showed that cost studies adopted significantly different
approaches to estimate costs of AD, reflecting a lack of consensus on the method-
ology of cost studies. CONCLUSIONS: Commenting on these quantitative results is
problematic because of the different approaches adopted to assess AD costs. To
increase its credibility, closer agreement among researchers on the methodological
principles of cost studies would be desirable.
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OBJECTIVES: To assess characteristics of a population with SB, treated in a tertiary
reference center. METHODS: Participants were recruited from the tertiary clinic
database or when initiating care in the clinic. Participants had to have a verifiable
SB diagnosis, and a cognitive ability to respond to the questionnaire or a caregiver
able to answer questions. Data were double-entered with queries issued to patients
to improve data quality. Descriptive analyses were used to summarize data.
RESULTS: Of 88 participants, 49 were male (44%), 38 female (56%), mean (SD) age
was 28.713.5 years (range: 3-68 years). In 15 participants (17%) the lesion was
located in the sacral region/occult, in 55 lumbar (63%), and in 18 (20%) at thoracic/
cervical level. The majority had myelomeningocele (n62), 19 had meningocele, 2
had lipomenigocele and 5 had occult lesion; 59 (67%) had a hydrocephalus, 58 of
those were shunted. Of 88, 63% always used a wheelchair, 26% answered they used
it often, whereas 11% never used wheelchairs. 20 participants needed splints on
feet/legs, 10 were able to walk using a walking aid. Those with hydrocephalus
needed a wheelchair at younger age, compared to those without hydrocephalus
(5.7 vs. 15.3 years). Of 71 adults, more than 50% had BMI 25 (overweight), in 20%
BMI was 30 (obese). The most frequent comorbidities were abnormal bladder
function/incontinence (90.9%), paralysis (73.9%), hydrocephalus (67.1%), orthope-
dic problems (56.8%) and loss of ambulation (51.1%). Less than 50% reported Arnold
Chiari malformation (47.7%), gastrointestinal/bowel disorders (46.6%), skin integ-
rity/pressure sores (37.5%), latex allergic reaction (36.4%), and eye problems (31.8%).
Among all participants, 54 lived with their parents, 13 with a partner, and 11 alone.
CONCLUSIONS: Results indicate that SB may have substantial impact on general
health, with large number of comorbidities that require lifelong treatment. Such
treatment contributes to the overall burden associated with SB.
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OBJECTIVES: To describe treatment patterns and resource consumption in pa-
tients with MS-related spasticity in Germany. METHODS: MOVE 1 (MObility Im-
proVEment) is a multi-centre, cross-sectional, retrospective burden-of-disease
study and combines a 12-month chart documentation with a patient questioning
at office-based neurologists, outpatients department at hospitals and rehabilita-
tion centers. Data were collected on demographical and clinical characteristics,
treatment patterns and resource consumption (e.g. drug treatment, physiotherapy,
OTC products). Direct costs were calculated from payer’s (statutory health insur-
ance) and patient’s perspective. RESULTS: In total, 419 patients were enrolled at 42
centers from 4-9/2011. 414 patients fulfilled selection criteria and were analyzed.
Mean age was 48.6 ( 9.6) years, 64.3% were female. According to physicians 27.3%
of patients had mild, 44.0% moderate and 28.7% severe spasticity. Onset of spas-
ticity was on average 8.2 ( 5.9) years before study inclusion. At study inclusion,
55.1% of patients had ongoing antispastic drug therapy (of these 55.3% received
baclofen). Percentages increased with increasing severity from 33.9% (mild) to
76.5% (severe). The majority of patients received drug mono-therapy (75.4%) or dual
therapy (20.2%). Overall, 37.7% of patients had used OTC products and dietary
supplements (of these 46.4% vitamins, 36.4% analgesics and 26.5% omega 3-fatty
acids). Within the last 12 months, 78.8% of patients had received physiotherapy
(mild: 66%; severe 86%). Mean costs per patient and year from payer perspective
amounted to €908 ( 991) for physiotherapy and €244 ( 467) for drugs. Stratified by
severity of spasticity, physiotherapy cost increases from €516 to €1351 and drug
cost from €85 to €458. Patients spent on average €14 ( 28) for drug co-payments,
€182 ( 208) for physiotherapy and €131 ( 319) for OTC products and dietary
supplements per year. CONCLUSIONS: This study provides first real-life data on
treatment patterns and resource consumption in patients with MS-related spas-
ticity in Germany.
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OBJECTIVES: To estimate economic value of informal care provided to patients in
situation of dependence with multiple sclerosis (MS). METHODS: Patients with MS
and their caregivers were identified through EDAD survey. The number of hours of
informal care provided was estimated. The method of cost replacement was used
to assess the economic value of this care. Two assessment scenarios were consid-
ered using “The Elderly in Spain” report (IMSERSO, 2008): the first one considered
the mean wage per hour of public service for home help of the 3 Autonomous
Regions of lower value, whereas the second scenario took into account the national
mean wage in order to estimate cost per hour. RESULTS: EDAD survey identified
368 patients with MS and some kind of disability. Average age was 64.26 years (SD:
16.82) and 73.91% were female. Average daily hours of care provided to people with
MS amounted to 10.27 (95% CI: 9.46 – 11.07). On an annual basis, average informal
care at home equalled 3,860 hours per MS patient. According to the assessment
scenarios considered, total mean costs of informal care at home ranged between
29,604 and 49,057 € per patient and year. When only the main informal carer at
home is considered, estimations yield 3,585 hours per MS patient and year,
whereas valuation ranged between 27,493 and 45,559 €. CONCLUSIONS: Informal
care of MS represents a high social burden. Dependence grade influences the need
to provide personal care. According to 2008 values, value of informal care provided
to people with MS is estimated at 29,604 – 49,057 € per patient and year.
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OBJECTIVES: Multiple sclerosis (MS) is one of the most frequent neurological dis-
eases and is associated with elevated health care costs. This study provides further
insights into these costs by differentiating between patients using different MS
drugs and by analysing different cost categories.METHODS: The database consists
of German claims data from 2006 to 2010. For the MS patients expenses of different
cost categories are analysed for each type of MS medication in the year 2009. These
categories cover costs for disease modifying drugs, symptomatic drug therapy,
primary care and hospitalization. RESULTS: In 2009, the mean annual costs per
patient amounted to roughly 15,000€ for disease modifying drugs and about 270€
for symptomatic drug therapy. Among the MS medications, Natalizumab caused
the highest treatment costs (25,104€), followed by Interferon beta-1a and Interferon
beta-1b with comparable costs (16,211€ and 16,519€) and Glatirameracetate
(12,617€). Azathioprine caused the lowest annual treatment costs (450€). The ex-
penditure for primary care (1,459€), hospital services (2,157€) and symptomatic
drug therapy (334€) is high for patients using Natalizumab, a drug which is indi-
cated for patients with highly active MS. Patients using Interferon beta-1a, Inter-
feron beta-1b and Glatirameracetate have similar expenses in those cost categories
(on average 872€ for primary care, 1409€ for hospital services and 212€ for symp-
tomatic drugs). Patients using Azathioprine have increased costs for symptomatic
drug therapy (316€) and hospital services (2,578€), while primary care expenditures
are comparable to patients using other basic MS therapy (770€). CONCLUSIONS:
The costs for specific MS medication makes up for 88% of the total annual drug
costs of MS patients. The expenses for other cost categories are similar for patients
treated with basic MS medication but higher for patients using escalating MS ther-
apy. Azathioprine is associated with lower medication costs but with slightly
higher expenses in the other observed cost categories.
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OBJECTIVES: To estimate the costs of multiple sclerosis according to severity of
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disease. METHODS: Total, direct and indirect costs were compared in 160 patients
divided into three groups categorized by disease severity: stage I Expanded Disabil-
ity Status Scale (EDSS2.5), stage II (EDSS 3- 4.5) and stage III (EDSS5). RESULTS:
The majority of these patients (94%) developed relapsing- remitting MS.A minority
of the patients (0.2-4 %) developed secondary progressive and primary progressive
MS. Cost evaluation was performed from the societal perspective and covered the
one-year period. The mean total cost/patient for one year was estimated at 27095,
27997and 31662$ for stage I, II and III, respectively. Both direct and indirect costs
increased with MS progression. For indirect cost the main item was productivity
loss. The mean extra medicine (treatments for MS symptoms and adverse effects of
medications) cost/patient for one year was calculated at 19036 $. CONCLUSIONS:
This study confirms that MS represents a high economic burden to patients and
society, with direct costs greatly exceeding indirect costs. As costs increase with
disease progression, treatment efforts should focus on patients in the early stages
of MS. Disease support system that monitors a variety of common progressive
signs for the MS individuals is a key element of a management program as well.
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OBJECTIVES: Direct cost comparison of glatiramer acetate (GA) and fingolimod for
the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in
Spain. METHODS: To compare GA and fingolimod a cost analysis model, based on
a 1-year time horizon, was developed. In addition to the pharmacological costs,
resource use was estimated for GA (1 hour of training with nursing staff in self-
injection techniques for subcutaneous administration) and fingolimod (vaccina-
tion for varicella-zoster virus in 5% of patients, 3 complete blood counts per year, 3
ophthalmology visits for prevention of macular edema, 3 transaminase tests to
monitor liver function, and cardiovascular monitoring consisting of 1 ECG before
the first fingolimod dose and at 6 hours; 1 day outpatients-hospital visit for cardi-
ological monitoring during 6 hours on the day of the first fingolimod dose, with
follow-up of blood pressure and heart rate every hour). The pharmacological costs
were calculated based on the ex-factory price of the drugs evaluated, using the
doses recommended in the respective SmPc. Total invoicing volume was dis-
counted by 7.5%, as laid down in Spanish Royal Decree 8/2010. Unitary costs were
obtained from the e-Salud database and the drug catalog. Costs in the model are
expressed in € 2012. RESULTS: The cost of annual treatment was €9,439.42 for GA
and €19,602.18 for fingolimod, yielding a cost difference of €10,162.76. Assuming a
fixed budget of €100,000.00, approximately 10 patients could be treated with GA,
compared to 5 with fingolimod. CONCLUSIONS: Fingolimod therapy requires twice
the investment of GA.
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OBJECTIVES: A model of Parkinson’s Disease (PD) progression over twenty-five
years was developed to assess long term economic consequences of slowing pro-
gression in a German setting. METHODS: Expected time to progression between
Hoehn and Yahr (H&Y) stages for the base case was based on a systematic literature
review identifying research since 1990 that reported survival analysis outcomes
(e.g., S(t), median time to progress). Costs, health utilities, mortality ratios, and
dementia likelihoods by H&Y stage were derived from published German and Aus-
trian data. Patients were assumed to be 50% H&Y 1 and 50% H&Y2 at baseline.
Hypothetical disease modification levels were assumed in comparative scenarios.
The model assessed the value of slowing progression versus the base case in costs,
quality-adjusted life-years (QALYs), and net health benefits (NMB), monetizing
QALYs at €50,000 and discounting outcomes at 3% annually. RESULTS: Ten man-
uscripts representing 44,612 patient-years reported longitudinal H&Y outcomes
usable in the model. Base case results indicated average costs of €396,897 and
average QALYs of 7.28 over 25 years. A scenario where the rate of disease progres-
sion was reduced by 20% from the base case resulted in NMB of €59,966 per patient,
including a €33,230 cost offset and 0.53 QALY gain. The NMB of a 100% reduction in
disease progression was €360,630 per patient. Results were most sensitive to as-
sumptions about annual direct medical costs and mortality rates by H&Y stage.
CONCLUSIONS: Costs of PD progression are substantial. Reducing progression
rates could produce significant economic gains for Germany.
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OBJECTIVES: To assess the cost-effectiveness of natalizumab in patients with
highly active relapsing/remitting multiple sclerosis (RRMS) in Mexico.METHODS:A
decision analytic model was developed based on the Kurtzke EDSS scale to esti-
mate the incremental cost per relapse avoided with natalizumab from the Mexican
Public Health care System perspective. Five-year costs of treating patients with MS
included drug acquisition costs, administration and monitoring costs, and costs of
treating MS relapses. Effectiveness was measured in terms of MS relapses avoided
(data from AFFIRM for natalizumab and meta-analysis for interferon and glati-
ramer acetate [GA]). Costs and effects were discounted at 5% annually. One-way
sensitivity analyses were conducted to assess uncertainty. RESULTS: Mean 5-year
estimated treatment costs were US$103,680 (natalizumab), US$78,980 (GA),
US$67,045 (GA after mitoxantrone induction) and US$125,204 (interferon plus GA).
Patients receiving natalizumab resulted in 1.04 expected relapses vs 6.47 for GA and
3.55 for interferon plus GA. Natalizumab dominated interferon plus GA in the in-
cremental cost-effectiveness analysis, as it was less costly and more effective in
reducing relapses. ICER for natalizumab vs GA was US$4,548 per relapse avoided
and vs GA after mitoxantrone induction was US$6,745. One-way sensitivity analy-
sis showed the results of the model were robust to changes in drug acquisition
costs, administration costs, and costs of treating MS relapses. CONCLUSIONS: Na-
talizumab is a cost-effective therapy for Mexican patients with highly active RRMS.
If natalizumab were used instead of interferon plus GA the public health care
system would obtain savings.
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OBJECTIVES: Genetic testing prevents sudden cardiac death (SCD) in asymptom-
atic first-degree relatives of patients with established inherited cardiopathies. The
objective is to estimate the cost-effectiveness of conducting genetic testing in first-
degree relatives of patients with Hypertrophic Cardiomyopathy (HCM), Arrhyth-
mogenic Right Ventricular Cardiomyopathy (ARVC), Long-QT Syndrome (LQTS),
Brugada Syndrome (BrS) or Catecholaminergic Polymorphic Ventricular Tachycar-
dia (CPVT). METHODS: A Markov model was developed to determine the cost per
life-year gained (LYG) and the symptom-free years (SFY) gained of using genetic
testing in first-degree relatives at risk of SCD due to gene-related cardiopathies.
The comparator was real world clinical practice (with no genetic testing). Four
health states were defined: 1) Asymptomatic; 2) Minor event; 3) Major event; and 4)
Death. The model was populated with data derived from the literature, local
sources of input costs and resources use, and expert opinion. The analysis was
conducted from the Spanish Health System (NHS) and social perspective in a hy-
pothetical cohort of 1,000 patients followed over their lifetime. All costs referred to
€,2012. Univariate and probabilistic sensitivity analysis were performed. RESULTS:
The mean cost per patient with genetic testing compared to usual practice was €
51,374 vs. € 72,611 for HCM, € 58,454 vs. € 80,337 for ARVC, € 20,575 vs. € 21,659 for
LQTS, € 38,005 vs. € 60,307 for BrS, and 28,286 vs. € 37,519 for CPTV, respectively. In
the case of LQTS and CPTV, genetic testing implied a mean increase in LYG of 0.96
and 0.04 years per patient, respectively. Genetic testing was dominant for LQTS and
CPTV and regarding HCM, ARVC and BrS was almost equally effective and less
costly compared with usual practice. Sensitivity analyses confirmed the consis-
tency of results. CONCLUSIONS: Compared to current practice with no screening,
genetic testing in first-degree relatives at risk of SCD is cost-effective for HCM,
ARVC, BrS, CPTV and LQTS in Spain.
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OBJECTIVES: The clinical efficacy of laquinimod in relapsing remitting multiple
sclerosis (RRMS) has been assessed in the randomized phase III clinical studies
ALLEGRO and BRAVO. In these studies, laquinimod showed a reduction in disabil-
ity progression measured by Expanded Disability Status Scale (EDSS) by 35.9% and
33.5% respectively, and a reduction in annualized relapse rate (ARR) by 23.0% and
21.3% respectively; all compared to placebo. In BRAVO a parallel group of patients
received interferon beta-1a IM which showed a 28.7% reduction in EDSS progres-
sion and 28.6% reduction in ARR. The purpose of this analysis was to investigate
health economic implications of these efficacy results.METHODS:A Markov model
was developed to estimate costs and health effects in the treatment of RRMS with
laquinimod, placebo and interferon beta-1a IM from a societal perspective in Swe-
den. The model included 10 health states defined by EDSS levels and used on-
treatment efficacy data from the pooled ALLEGRO and BRAVO trials. Off-treatment
efficacy data as well as costs and quality of life data for Sweden were taken from
published articles. The analysis did not include pharmaceutical costs. Costs and
health effects were discounted at a rate of 3.0%. RESULTS: Therapy with laquini-
mod during 5 years and a total time horizon of 40 years resulted in a gain of 0.21
quality adjusted life years and societal cost savings of €28 000 (0.1115 €/SEK) com-
pared to placebo. The corresponding figures for interferon beta-1a were 0.09 qual-
ity-adjusted life years and €13 000. The results were stable for reasonable variation
of most parameters. In particular, sensitivity analyses showed that EDSS progres-
sion was a much stronger driver of results than ARR. CONCLUSIONS: Laquinimod
is associated with better health effects and lower overall non-pharmaceutical
management costs than placebo as well as interferon beta-1a IM due to its favor-
able effect on EDSS progression.
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